Our Leadership

Management Board

Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development, and commercialization. All members of the Management Board are also part of the Operating Team.


John Maraganore, PhD

Chief Executive Officer

Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam.

Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.

Barry Greene


Barry Greene joined Alnylam in 2003 and has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology industries.

Prior to Alnylam, Barry was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult. Preceding that, Barry’s past experiences include Vice President of Marketing and Customer Services for AstraZeneca, formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and Partner, Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice.

Barry received his Bachelor of Science degree in Industrial Engineering from University of Pittsburgh and served as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Boards of Acorda Therapeutics and Karyopharm Therapeutics.


Yvonne Greenstreet, MBChB, MBA

Chief Operating Officer

Dr. Yvonne Greenstreet possesses 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management. She has successfully led product development and commercialization teams in a wide range of therapy areas, bringing new medicines to patients.

Yvonne was previously Senior Vice President and Head of Medicines Development at Pfizer, and a member of the executive team for the specialty business, with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, Yvonne held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe.

Yvonne received her medical degree (MBChB) from the University of Leeds, UK, and an MBA degree from INSEAD, France. She serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, and Indivior PLC, a global specialty pharmaceutical business. Dr. Greenstreet also serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation.


Pushkal Garg, MD

Chief Medical Officer

Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam.

Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.

Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ).


Laurie Keating, JD


Laurie Bartlett Keating joined Alnylam in 2014 with more than 25 years of executive experience at high-growth technology and biotechnology companies.

Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high-growth technology companies, including Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team. Based on her leadership at Sybase, Laurie was named one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Laurie practiced law at McCutchen, Doyle, Brown and Enersen (which became Bingham McCutchen and is now a part of Morgan, Lewis & Bockius) in San Francisco.

She has a Doctor of Jurisprudence degree from the University of California, Hastings College of the Law, and a BA in Economics from the University of California at Berkeley. Laurie is a member of the Board of Directors of Imbria Pharmaceuticals and MassBio, and a past chair of the BIO General Counsels Committee.




Dr. Saraswathy (Sara) Nochur joined Alnylam in 2006 as the Vice President of Regulatory Affairs, and also held roles as Program Leader for 2 late-stage programs. She was promoted to Senior Vice President in 2012, and also had Quality Assurance reporting to her. During her time at Alnylam, she has been instrumental in the clinical evaluation of a number of different drug RNAi candidates and in building the Regulatory teams in the United States. and Europe, comprising overall regulatory strategy, CMC strategy, regulatory operations, and Ad-Promo/labeling. Dr. Nochur is an executive co-sponsor (along with Barry Greene) of Alnylam’s Diversity & Inclusion initiative.

Dr. Nochur has been in the biotechnology industry since 1989. Prior to Alnylam, she held the position of Vice President, Regulatory Affairs at The Medicines Company. Before her 4 years there, Dr. Nochur served as Director, Product Development and Regulatory Affairs for CereMedix, Inc. She also held senior positions at BioTrack, Inc. Dr. Nochur started her career as a scientist at DynaGen, Inc., and worked on regulatory submissions for in vitro diagnostics as well as drugs, culminating in the role of Director, New Product Development.

Dr. Nochur received her BS and MS degrees in Microbiology from the University of Bombay in India, and her PhD in Biochemical Engineering at the Massachusetts Institute of Technology.

Jeff Poulton

Chief Financial Officer

Jeff joined Alnylam as CFO in August 2019. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US.

Between 2003 and December 2017, Jeff held various roles of increasing responsibility at Shire Plc, culminating in his service as Chief Financial Officer and a member of Shire’s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Jeff also led Shire’s rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Jeff led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp and PPG Industries. Jeff also served in the United States Navy as a Commissioned Officer.

Jeff holds a BA in Economics from Duke University and an MBA in Finance from the Kelley School of Business at Indiana University. He is a member of the Board of Directors of EIP Pharmaceuticals.


Akshay Vaishnaw, MD, PhD

PRESIDENT, Research & Development

Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006 as VP Clinical Research and has then subsequently served in various R&D roles with increasing responsibility.  Akshay is currently the President of R&D.  At Alnylam he leads the discovery and development of their pipeline of RNAi therapeutics, which includes the recently approved compound, Onpattro for hATTR amyloidosis with peripheral neuropathy.  Prior to 2006, he was at Biogen as Senior Director, Translational Medicine.  In his seven years at Biogen, Akshay was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (AMEVIVE™) for chronic plaque psoriasis.

Akshay received his M.D. from the University of Wales College of Medicine, U.K., and Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K.  He is a Fellow of the Royal College of Physicians, U.K.  Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra, Inc.

Kelley Boucher

Chief Human Resource Officer

Kelley Boucher joined Alnylam in 2019 bringing nearly 20 years of experience within the biotechnology and medical device industries. She oversees the global HR organization which includes talent planning & strategy, organizational effectiveness, talent acquisition, learning & development, total rewards, and HR systems.

Prior to Alnylam, Kelley served as Vice President and Global Head of Human Resources at Abiomed for three years as the company experienced exponential growth and commercial execution. Before her time at Abiomed, Kelley spent 10 years at Shire where she held a variety of roles across HR, eventually becoming Vice President and Head of Human Resources for Technical Operations and then Shire’s Corporate Divisions. She also managed the organizational design component of multiple acquisitions. Prior to Shire, Kelley was a Principal Consultant at Clockwork Consulting (a pharmaceutical recruitment firm) and worked at Syntonix Pharmaceuticals (acquired by Biogen) and Digitas. She was honored with the Healthcare Business Women’s Association Rising Star award in 2013. Kelley is a member of the Healthcare Business Women’s Association (HBA), the Human Resources Leadership Forum (HRLF) and the Corporate Executive Board (CEB).

Kelley attended Cornell University where she received her Bachelor of Arts in government relations and the Darden School of Business at the University of Virginia where she completed her studies in the Strategic Leadership Development executive program.

Board of Directors

The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA interference) therapeutics.

Michael W. Bonney


Executive Chair and former Chief Executive Officer of Kaleido Biosciences; former Partner of Third Rock Ventures; former Chief Executive Officer and Director of Cubist Pharmaceuticals; Chair of the Board of Directors of Magenta Therapeutics; Director of Bristol Myers Squibb Company, former Director of Syros Pharmaceuticals and Sarepta Therapeutics.

Dennis A. Ausiello, MD

Director of the Center for Assessment Technology and Continuous Health (CATCH); Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Physician‐in‐Chief Emeritus at Massachusetts General Hospital; Member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences; Director of Seres Therapeutics.

Olivier Brandicourt, MD

Senior Advisor at Blackstone Group, former Chief Executive Officer and Director of Sanofi, former Chief Executive Officer and Chair of Bayer HealthCare, former President and General Manager of the Emerging Markets and Established Products business units, and member of the Executive Leadership Team of Pfizer Inc.

Marsha H. Fanucci

Former Chief Financial Officer of Millennium Pharmaceuticals; Chair of the Board of Directors of Cyclerion Therapeutics; Director of Syros Pharmaceuticals.

Margaret A. Hamburg, MD

Former Commissioner of the U.S. Food & Drug Administration (FDA); Foreign Secretary of the National Academy of Medicine (NAM); Chair of the Board of the American Association for the Advancement of Science (AAAS).

John M. Maraganore, PhD

Chief Executive Officer of Alnylam; Member of the Board of Directors of Agios Pharmaceuticals; Member and former Chair of the Biotechnology Industry Organization (BIO).

Steven M. Paul, MD

Chairman of the Board, President and Chief Executive Officer of Karuna Therapeutics and board member of Voyager Therapeutics, Inc.; Venture Partner at Third Rock Ventures; co-founder and board member of SAGE Therapeutics; trustee for the Foundation for the National Institute of Mental Health (NIH); former President of the Lilly Research Laboratories of Eli Lilly and Company; former Scientific Director of the National Institute of Mental Health and adjunct professor of Psychiatry at Washington University of St. Louis School of Medicine.

David E.I. Pyott

Former Chair and Chief Executive Officer of Allergan; Member of the Supervisory Board of Royal Philips in the Netherlands; Director of BioMarin Pharmaceutical, former Lead Director of Avery Dennison Corporation.

Colleen F. Reitan

Former President of Plan Operations and Chief Operating Officer of Health Care Service Corporation (HCSC); former President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota. Director of Myriad Genetics and Cricket Health.

Amy W. Schulman, JD

Managing Partner, Polaris Partners; Co-founder, Executive Chair, and former Chief Executive Officer of Lyndra Therapeutics; Executive Chair of SQZ Biotech; Senior Lecturer at Harvard Business School; former Executive Vice President and General Counsel of Pfizer; served as the Business Unit Lead for Pfizer Consumer Healthcare; Director of Cyclerion Therapeutics.

Phillip A. Sharp, PhD

Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Founding Director of McGovern Institute for Brain Research, MIT; Nobel Laureate; Founder of Alnylam; Co-founder and former Director of Biogen; Member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences; Director of Syros Pharmaceuticals and Vir Biotechnology.


Receive news and updates on the work at Alnylam that affects you most.